- Home
- ADAG vs PYPD Comparison
ADAG vs PYPD Comparison
Compare ADAG & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADAG | PYPD |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.3M | 77.4M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ADAG | PYPD |
|---|---|---|
| Price | $2.91 | $4.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $8.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 62.1K | 41.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3,688.61 | N/A |
| Revenue Next Year | $17.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $2.30 |
| 52 Week High | $3.53 | $5.12 |
Technical Indicators
Market Signals| Indicator | ADAG | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 58.05 | 48.03 |
| Support Level | $1.64 | $4.26 |
| Resistance Level | $3.19 | $4.38 |
| Average True Range (ATR) | 0.24 | 0.17 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 47.88 | 68.29 |
Price Performance
Historical ComparisonAbout ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.